Ovid Therapeutics Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019; filed March 11, 2020. The filing is an annual report, although it includes unaudited fourth-quarter data. Ovid is a clinical-stage biopharmaceutical company developing medicines for rare neurological disorders and has not generated commercial product revenue.
Business Context and Pipeline
- OV101 (gaboxadol): Lead program targeting Angelman syndrome and Fragile X syndrome through modulation of extrasynaptic GABAA receptors. The Phase 2 STARS trial in Angelman syndrome met its safety and tolerability endpoint and showed statistically significant improvement on the physician-rated CGI-I endpoint for the once-daily group.
- NEPTUNE: Pivotal Phase 3 Angelman syndrome trial initiated in 2019, targeting approximately 60 patients aged 4 to 12. Topline data were expected by mid-2020.
- ROCKET and SKYROCKET: Fully enrolled Phase 2 and observational studies, respectively, in Fragile X syndrome; data were expected in early second-quarter 2020.
- OV935 (soticlestat/TAK-935): Jointly developed with Takeda for severe developmental and epileptic encephalopathies, including Dravet syndrome, Lennox-Gastaut syndrome, CDKL5 Deficiency Disorder and Dup15q syndrome. Phase 2 ELEKTRA and ARCADE trials were ongoing, with results expected in 2020.
Financial Performance and Liquidity
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No commercial revenue |
| Research and development expense | $42.2 million | $33.8 million | Up $8.4 million |
| General and administrative expense | $19.3 million | $19.1 million | Up $0.1 million |
| Total operating expenses | $61.4 million | $52.9 million | Up $8.5 million |
| Loss from operations | $(61.4) million | $(52.9) million | Loss increased |
| Interest income | $0.9 million | $1.0 million | Down slightly |
| Net loss | $(60.5) million | $(52.0) million | Loss increased $8.5 million |
| Net loss per share | $(1.54) | $(2.11) | Improved due primarily to share issuance |
| Operating cash flow | $(51.1) million | $(45.6) million | Cash use increased $5.5 million |
| Cash, cash equivalents and short-term investments | $76.7 million | $41.5 million | Up $35.2 million |
| Working capital | $69.3 million | $35.4 million | Up $33.9 million |
| Total liabilities | $10.8 million | $8.8 million | Up $2.0 million |
R&D expense increased primarily because of higher development activity. The 2019 R&D expense included a $4.7 million reduction for Takeda-reimbursable collaboration costs, compared with a $1.3 million reduction in 2018. Stock-based compensation was $5.2 million in 2019 versus $7.1 million in 2018.
The company had no long-term debt, operating leases or material non-cancelable purchase commitments reported as of December 31, 2019. Management stated that existing liquidity was expected to fund current operating plans for at least 12 months from the filing date, but additional capital will be required to continue development and support potential commercialization.
Material Changes Versus the Prior Period
- R&D spending rose 25% to $42.2 million as clinical development programs advanced, including initiation of NEPTUNE and continued OV935 trials.
- Net loss increased from $52.0 million to $60.5 million, while operating cash use increased from $45.6 million to $51.1 million.
- Liquidity improved substantially following equity financings: approximately $64.1 million of net proceeds from February and October offerings and $22.3 million from the at-the-market program.
- Common shares outstanding increased to 54.7 million at year-end 2019 from 24.7 million at year-end 2018, creating significant dilution for existing holders.
- Ovid hired a Chief Commercial Officer in November 2019 to begin preparing for a potential commercial organization if OV101 data were positive.
- The company settled a dispute with Catalyst Pharmaceuticals in May 2019 and retained its rights under the Northwestern license.
Guidance, Outlook, Risks and Unusual Items
- Management expects continued losses and negative operating cash flow for at least the next several years and does not expect drug-sales revenue unless and until a candidate receives regulatory approval and is commercialized.
- Key anticipated milestones included NEPTUNE topline data by mid-2020, ROCKET and SKYROCKET data in early second-quarter 2020, ARCADE data in first-quarter 2020 and ELEKTRA topline data in third-quarter 2020.
- Potential contingent payments under licensing and collaboration agreements totaled up to approximately $279.3 million, including up to $189.0 million to Lundbeck, up to $5.3 million to Northwestern and approximately $35.0 million of remaining potential Takeda commercial and regulatory milestones. These amounts were excluded from contractual obligations because payment timing and probability were not reasonably estimable.
- Upon the first patient enrollment in the first Phase 3 trial for an initial Takeda indication, Ovid may be required to issue Takeda shares equal to the lesser of 8% of outstanding capital stock or $50.0 million divided by the applicable share price, subject to specified conditions.
- Clinical and regulatory risks include failure to replicate STARS results, inconclusive Phase 3 data, safety events, unclear endpoints in rare neurological disorders, enrollment challenges and possible delays from the coronavirus outbreak.
- Ovid relies on Lundbeck and third-party manufacturers for OV101 and on Takeda for OV935 supply. Manufacturing, supply, collaboration, intellectual property, reimbursement and regulatory approval risks could materially affect the programs.
- OV935 exploratory seizure reductions were based on small, early-stage and partly open-label studies. The filing cautions that preliminary and interim results may change as additional data become available.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and no income tax provision because of operating losses and a full valuation allowance against deferred tax assets.
Most Important Facts for Investors to Verify
- Whether NEPTUNE demonstrates efficacy and acceptable safety sufficient to support an OV101 Angelman syndrome regulatory filing.
- Final, audited results from ROCKET, ARCADE, ELEKTRA and ENDYMION, including the durability and statistical strength of any efficacy signals.
- Cash-burn trends, remaining liquidity and the timing and terms of future financing, including potential dilution from equity offerings and Takeda-related securities.
- The probability, timing and cash-versus-equity settlement terms of Lundbeck, Northwestern and Takeda milestone obligations.
- Manufacturing readiness, pediatric formulation progress and regulatory feedback for OV101.
- Any clinical-trial disruptions, enrollment delays, safety findings or supply-chain effects related to the coronavirus outbreak or other operational events.
- Patent validity, remaining patent terms and the company’s ability to maintain exclusive rights to OV101 and OV935.